Heuron Gets FDA Green Light for Stroke Triage and Notification Solution

SAN JOSE, Calif.–(BUSINESS WIRE)–Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea, announced that its non-contrast CT imaging analysis solution, Heuron ICH, has received FDA 510(k) clearance. This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea for computer-aided triage and notification devices (CADt).




Heuron ICH is an advanced AI solution designed to automatically screen and signal potential cases of intracranial hemorrhage, relying solely on non-contrast CT images. Its primary function is to swiftly discern emergency brain hemorrhages that require immediate attention, even capturing the minutest hemorrhages that often elude human detection. Notably, Heuron ICH boasts a sensitivity of 86% and specificity of 88%, ensuring reliable and accurate assistance in critical medical scenarios.

Heuron ICH becomes the fifth solution from Heuron to receive FDA clearance, following Veuron-Brain-mN1, Veuron-Brain-pAb, Heuron Beta Amyloid, and Veuron-Brain-pAb3. Currently, Heuron holds 15 domestic medical device approvals/certifications, four European CE (MDD) certifications, and various other international certifications.

Donghoon Shin, CEO of Heuron, expressed, “Securing this product approval marks a significant milestone, facilitating our swift penetration into the U.S. market. Our commitment extends beyond this achievement as we endeavor to expand our portfolio of FDA-approved medical solutions. We are dedicated to optimizing the utilization of Heuron’s diverse offerings within U.S. clinical environments, particularly for emergency patient care.”

Additionally, Heuron ICH successfully achieved the performance levels required by the FDA through clinical trials conducted last year in collaboration with Mass General Brigham, affiliated with Harvard Medical School.

About Heuron

Heuron Co., Ltd., founded in 2017, pioneers medical AI solutions for neurodegenerative diseases and emergency stroke care. Heuron’s cutting-edge software aids precise diagnosis of conditions like Alzheimer’s and Parkinson’s disease while expediting stroke treatment through the StroCare Suite™. Collaborating globally, Heuron strive to enhance brain health through AI-driven diagnostics, addressing challenges posed by aging populations. For more information, please visit: https://iheuron.com/en/

Contacts

Eunsil Kang

Chief Strategy Officer

[email protected], [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.